Petmed Express (PETS) AI Stock Analysis

• Market Cap: $35.31M
• Dividend Yield: N/A
• Average Volume (3M): 159.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.43
• Revenue Growth: -19.25%
• EPS Growth: 14.47%
• Country: US
• Employees: 287
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): N/A
• Shares Outstanding: 21,015,558
• 10 Day Avg. Volume: 258,705
• 30 Day Avg. Volume: 159,958
• PEG Ratio: 0.73
• Price to Book (P/B): 1.01
• Price to Sales (P/S): 0.38
• P/FCF Ratio: -218.47
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.12
• Revenue Forecast (FY): $216.21M

• Rating: 43 Neutral
• Price Target: $1.50 ▼(-41.63% Downside)

Petmed Express faces significant financial and technical challenges. The company's declining revenues and profitability issues are compounded by bearish technical indicators and a negative P/E ratio. These factors suggest a cautious outlook for the stock.

Positive Factors

Strong Balance Sheet

A strong balance sheet with low leverage provides financial stability and flexibility, allowing the company to navigate challenges and invest in growth opportunities.

Stable Gross Profit Margin

A stable gross profit margin indicates effective cost management, which is crucial for maintaining profitability amidst revenue fluctuations.

Management Changes

New leadership can bring fresh perspectives and strategies, potentially improving operational efficiency and strategic direction, which is vital for long-term success.

Negative Factors

Declining Revenue

Declining revenue indicates challenges in market competitiveness and customer retention, which can impact long-term growth and profitability.

Profitability Challenges

Ongoing profitability issues suggest operational inefficiencies and market pressures, which can hinder investment in growth and innovation.

Cash Flow Issues

Weak cash flow generation limits the company's ability to reinvest in the business, pay down debt, and return capital to shareholders, affecting long-term sustainability.

Petmed Express Business Overview & Revenue Model

Company Description

PetMed Express, Inc. (PETS) is a leading online pet pharmacy that specializes in providing prescription and non-prescription pet medications, health products, and supplies directly to pet owners. The company caters primarily to the companion animal sector, including dogs and cats, and offers a wide range of products such as flea and tick control, heartworm prevention, vitamins, and dental care items. By leveraging an e-commerce platform, PetMed Express aims to enhance the accessibility and affordability of pet healthcare products.

How the Company Makes Money

PetMed Express generates revenue primarily through the sale of pet medications and health products. The company's revenue model is built on both prescription and over-the-counter products, with a significant focus on recurring purchases like monthly flea and tick treatments. The company also benefits from partnerships with veterinarians, enabling them to facilitate prescription fulfillment and reach a wider customer base. Additional revenue streams may include product sales related to pet supplies and nutritional supplements. Marketing efforts, including promotions and customer loyalty programs, further contribute to driving sales and enhancing customer retention.

Petmed Express Financial Statement Overview

Summary

Petmed Express is facing financial challenges with declining revenues and profitability issues. The balance sheet remains strong with low leverage, but cash flow concerns persist. The company needs to address its profitability and cash flow generation to improve its financial health.

Income Statement

Petmed Express has experienced declining revenue over the past year, with a revenue growth rate of -8.11%. The company is facing profitability challenges, as evidenced by negative net profit and EBIT margins. However, the gross profit margin remains relatively stable at 30.46%, indicating some resilience in cost management.

Balance Sheet

The balance sheet shows a strong equity position with a low debt-to-equity ratio of 0.0117, suggesting low financial leverage and risk. However, the return on equity is negative, reflecting the company's recent losses. The equity ratio is healthy, indicating a solid capital structure.

Cash Flow

Cash flow analysis reveals a significant decline in free cash flow, with a growth rate of -146.15%. The operating cash flow to net income ratio is low, indicating challenges in converting income into cash. The negative free cash flow to net income ratio further highlights cash flow issues.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	226.97M	226.97M	281.06M	256.86M	273.42M	303.58M
Gross Profit	67.42M	69.14M	78.65M	71.01M	76.94M	84.32M
EBITDA	6.71M	6.71M	-1.11M	10.99M	27.03M	32.96M
Net Income	-6.27M	-6.27M	-7.46M	5.14M	18.72M	23.92M
Balance Sheet
Total Assets	148.70M	148.70M	169.88M	167.48M	176.32M	187.50M
Cash, Cash Equivalents and Short-Term Investments	54.72M	54.72M	55.30M	104.09M	111.08M	118.72M
Total Debt	996.00K	996.00K	1.45M	995.00K	0.00	0.00
Total Liabilities	63.57M	63.57M	73.15M	57.51M	34.13M	46.22M
Stockholders Equity	85.13M	85.13M	96.73M	123.80M	142.19M	141.28M
Cash Flow
Free Cash Flow	-395.00K	-395.00K	-194.00K	22.54M	16.75M	37.64M
Operating Cash Flow	4.72M	4.72M	4.32M	27.80M	18.50M	40.08M
Investing Cash Flow	-5.11M	-5.11M	-40.67M	-10.26M	-1.75M	-2.43M
Financing Cash Flow	-181.00K	-181.00K	-12.44M	-24.54M	-24.38M	-22.69M

Petmed Express Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.57
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PETS, the sentiment is Negative. The current price of 2.57 is above the 20-day moving average (MA) of 2.31, above the 50-day MA of 2.50, and below the 200-day MA of 3.33, indicating a bearish trend. The MACD of -0.24 indicates Positive momentum. The RSI at 27.77 is Positive, neither overbought nor oversold. The STOCH value of 2.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PETS.

Petmed Express Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LFMD	47 Neutral	$185.32M	―	―	―	30.71%	73.43%
PETS	43 Neutral	$35.31M	―	―	―	-19.25%	14.47%
SRZN	43 Neutral	$107.90M	-0.90	―	―	-63.96%	-28.50%
ADAG	42 Neutral	$80.12M	-2.64	-63.41%	―	-87.59%	11.53%
YI	38 Underperform	$38.38M	-3.73	―	―	-3.54%	77.98%

Petmed Express Corporate Events

PetMed Express Faces Nasdaq Compliance Notice

PetMed Express, Inc. announced on November 13, 2025, that it received a notice from Nasdaq due to delays in filing its quarterly reports for periods ending June 30 and September 30, 2025. This non-compliance with Nasdaq’s listing rules requires the company to update its compliance plan by November 28, 2025. The notice does not immediately affect the company’s stock listing, and PetMed is working to complete the filings promptly. Additionally, preliminary second-quarter results indicate a decline in net sales compared to the previous year, with estimated sales ranging from $43.4 million to $44.5 million.

The most recent analyst rating on (PETS) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Petmed Express stock, see the PETS Stock Forecast page.

PetMed Express Delays Quarterly Report Filing

PetMed Express, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the period ending September 30, 2025. The delay is primarily due to the need to first complete and file the previous quarter’s report, which was postponed due to an investigation by the company’s Audit Committee. The company expects to file the delayed report within five calendar days following the due date. Preliminary financial results indicate a significant decrease in net sales compared to the same period last year, with sales estimated between $43.4 million and $44.5 million for the three-month period. The company is also analyzing a potential goodwill impairment charge. PetMed Express is actively working on compliance, with the notification signed by Douglas Krulik, Chief Accounting Officer and Interim Principal Financial Officer.

The most recent analyst rating on (PETS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Petmed Express stock, see the PETS Stock Forecast page.

Petmed Express Appoints Interim CEO and President

On October 19, 2025, PetMed Express appointed James LaCamp as a director and Audit Committee Chair, effective immediately. LaCamp, with nearly two decades of experience in finance and accounting, is expected to enhance the company’s financial governance and oversight. Additionally, on October 20, 2025, the company entered into an Interim Executive Employment Agreement with Leslie C.G. Campbell, who will serve as Interim CEO and President for a year, highlighting the company’s strategic focus on board composition and leadership to drive growth and shareholder value.

The most recent analyst rating on (PETS) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Petmed Express stock, see the PETS Stock Forecast page.

PetMed Express Announces $1.2 Million Trade Name Impairment

On October 1, 2025, PetMed Express announced a $1.2 million non-cash impairment of its PCRX trade name for the quarter ended March 31, 2025, due to reduced actual and forecasted revenues. This impairment does not require future cash expenditures but highlights potential financial challenges, as the company also faces a sustained decline in its stock price, which may indicate further goodwill impairments affecting its financial condition and capital access.

The most recent analyst rating on (PETS) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Petmed Express stock, see the PETS Stock Forecast page.

PetMed Express Approves Salary for Interim CEO

On September 8, 2025, PetMed Express, Inc.’s Board of Directors approved an initial annual base salary of $550,000 for Leslie C.G. Campbell, who began her role as Interim CEO and President on August 11, 2025. Additionally, the Board granted a restricted stock award of 10,000 shares to Douglas Krulik, the Chief Accounting Officer and Interim Principal Financial Officer, under the company’s 2024 Omnibus Incentive Plan, with the award vesting six months after the grant date.

The most recent analyst rating on (PETS) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Petmed Express stock, see the PETS Stock Forecast page.

PetMed Express Faces Nasdaq Compliance Deadline

On August 20, 2025, PetMed Express received a notice from Nasdaq due to a delay in filing its Annual and Quarterly Reports, leading to non-compliance with Nasdaq’s listing rules. The company has until September 1, 2025, to submit a compliance plan, and if accepted, it could have until December 29, 2025, to regain compliance. The notice does not immediately affect the company’s stock listing, and PetMed Express is working diligently to file the reports promptly.

The most recent analyst rating on (PETS) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Petmed Express stock, see the PETS Stock Forecast page.